3-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)phenol | 939386-93-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 3-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)phenol
• CAS: 939386-93-3
• 化学式: C₁₇H₁₄N₂O
• 分子量: 262.311
• InChiKey: QWZWERACKRKIAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.27
• 重原子数：
  20.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  48.38
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  3-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)phenol 在 sodium tetrahydroborate 作用下， 生成 3-(2,3,4,9-tetrahydro-1H-β-carbolin-1-yl)-phenol
  参考文献：
  名称：

  M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: Serominic compounds

  摘要：

  Chronic low-dose treatment of rats with the psychomimetic drug, phencyclidine, induces regionally specific metabolic and neurochemical changes in the CNS that mirror those observed in the brains of schizophrenic patients. Recent evidence suggests that drugs targeting serotoninergic and muscarinic receptors, and in particular 5-HT7 antagonists and M-4 agonists, exert beneficial effects in this model of schizophrenia. Compounds that display this combined pattern of activity we refer to as serominic compounds. Based upon leads from natural product screening, we have designed and synthesised such serominic compounds, which are principally arylamidine derivatives of tetrahydroisoquinolines, and shown that they have the required serominic profile in ligand binding assays and show potential antipsychotic activity in functional assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.093
• 作为产物：
  描述：

  3-hydroxy-N-[2-(1H-indol-3-yl)ethyl]benzamide 在 三氯氧磷 作用下， 生成 3-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)phenol
  参考文献：
  名称：

  M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: Serominic compounds

  摘要：

  Chronic low-dose treatment of rats with the psychomimetic drug, phencyclidine, induces regionally specific metabolic and neurochemical changes in the CNS that mirror those observed in the brains of schizophrenic patients. Recent evidence suggests that drugs targeting serotoninergic and muscarinic receptors, and in particular 5-HT7 antagonists and M-4 agonists, exert beneficial effects in this model of schizophrenia. Compounds that display this combined pattern of activity we refer to as serominic compounds. Based upon leads from natural product screening, we have designed and synthesised such serominic compounds, which are principally arylamidine derivatives of tetrahydroisoquinolines, and shown that they have the required serominic profile in ligand binding assays and show potential antipsychotic activity in functional assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.093